17 completed, 5 terminated, 2 unknown, 1 active not recruiting. 25 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 25 | Completed 17, Terminated 5, Unknown 2, Active not recruiting 1 |
| Phase 2 | 7 | Completed 3, Unknown 2, Active not recruiting 1, Terminated 1 |
Follow Prolymphocytic Leukemia: new trials by email Literature Review of Prolymphocytic Leukemia trials Research Report on Prolymphocytic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22 anti-CD19/22-CAR vector-transduced T cells - Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 / Phase 2 | Unknown | Chinese PLA General Hospital | 30 | 2017-08-01 | 2019-04-17 |
| Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20 anti-CD19/20-CAR vector-transduced T cells - Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 / Phase 2 | Completed | Chinese PLA General Hospital | 100 | 2017-04-01 | 2020-09-02 |
| Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma Selinexor, Ibrutinib, Pharmacological Study - Prolymphocytic Leukemia, Recurrent Adult Diffuse Large Cell Lymphoma | Phase 1 | Completed | Jennifer Woyach | 34 | 2015-06-09 | 2025-06-10 |
| Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL acalabrutinib, Obinutuzumab, Venetoclax - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1 | Completed | Acerta Pharma BV | 69 | 2014-12-22 | 2025-12-19 |
| ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia Acalabrutinib - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Acerta Pharma BV | 306 | 2014-01-30 | 2026-05-05 |
| Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy anti-CD20-CAR vector-transduced autologous T cells, genetically engineered lymphocyte therapy - Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 / Phase 2 | Unknown | Chinese PLA General Hospital | 50 | 2013-01-01 | 2015-09-29 |
| Allogeneic Stem Cell Transplant for CLL Allogeneic Hematopoietic Stem Cell Transplantation, Anti-Thymocyte Globulin, Busulfan - Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 15 | 2012-11-21 | 2020-02-24 |
| Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant tetanus-CMV fusion peptide vaccine, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 | Completed | City of Hope Medical Center | 36 | 2012-10-29 | 2024-04-02 |
| Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia Dinaciclib, Laboratory Biomarker Analysis, Ofatumumab - Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 36 | 2012-01-01 | 2018-03-15 |
| Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia cefepime hydrochloride - Adult Acute Lymphoblastic Leukemia, Adult Acute Myeloid Leukemia | Phase 1 | Completed | Wake Forest University Health Sciences | 70 | 2011-02-01 | 2018-07-18 |
| MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia Akt inhibitor MK2206, diagnostic laboratory biomarker analysis, pharmacological study - Accelerated Phase Chronic Myelogenous Leukemia, Acute Leukemias of Ambiguous Lineage | Phase 1 | Completed | National Cancer Institute (NCI) | 45 | 2011-01-01 | 2014-04-29 |
| Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers Laboratory Biomarker Analysis, Lenalidomide, Pharmacological Study - Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 | Phase 1 | Completed | National Cancer Institute (NCI) | 17 | 2010-11-24 | 2017-09-25 |
| Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL) carfilzomib, Cytokine Assessment, Pharmacodynamic Studies - B-cell Chronic Lymphocytic Leukemia, Hematopoietic/Lymphoid Cancer | Phase 1 | Completed | Ohio State University Comprehensive Cancer Center | 21 | 2010-10-01 | 2016-05-09 |
| AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma Pharmacodynamic Studies, Fatigue Inventory, Pharmacogenomic studies - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Completed | Amir Mortazavi | 44 | 2010-05-04 | 2018-06-04 |
| Alvespimycin Hydrochloride in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia alvespimycin hydrochloride, diagnostic laboratory biomarker analysis, pharmacogenomic studies - B-cell Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia | Phase 1 | Terminated | National Cancer Institute (NCI) | 30 | 2010-05-01 | 2015-11-04 |
| Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma azacitidine, bortezomib, Correlative studies - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Completed | Pierluigi Porcu | 8 | 2010-05-01 | 2013-12-03 |
| Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Alvocidib Hydrochloride, Cyclophosphamide, Diagnostic Laboratory Biomarker Analysis - Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia | Phase 1 | Terminated | National Cancer Institute (NCI) | 9 | 2010-04-01 | 2015-11-11 |
| CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy CART-19 - Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 | Completed | University of Pennsylvania | 26 | 2010-03-17 | 2023-06-22 |
| Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy sunitinib malate, pharmacological study, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Phase 1 | Completed | National Cancer Institute (NCI) | 42 | 2009-08-01 | 2014-03-17 |
| Lenalidomide and Alvocidib in Treating Patients With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Alvocidib Hydrochloride, Lenalidomide, Pharmacological Study - Anemia, Chronic Lymphocytic Leukemia | Phase 1 | Completed | National Cancer Institute (NCI) | 39 | 2008-08-01 | 2015-04-02 |
Showing 20 of 25. Sign in to see all of them.
Leukemia, Prolymphocytic (25) · Leukemia, Lymphocytic, Chronic, B-Cell (24) · Lymphoma, Mantle-Cell (13) · Lymphoma, Follicular (12) · Lymphoma, Large B-Cell, Diffuse (12) · Burkitt Lymphoma (8) · Lymphoma, B-Cell, Marginal Zone (8) · Lymphoma, Large-Cell, Anaplastic (8) · Mycosis Fungoides (8) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (8) · Sezary Syndrome (8) · Lymphoma, Extranodal NK-T-Cell (7) · Lymphoma, Non-Hodgkin (7) · Lymphoma, T-Cell, Cutaneous (7) · Hodgkin Disease (6)
Hematologic Diseases (25) · Hemic and Lymphatic Diseases (25) · Immune System Diseases (25) · Immunoproliferative Disorders (25) · Leukemia, Lymphoid (25) · Lymphatic Diseases (25) · Lymphoproliferative Disorders (25) · Neoplasms (25) · Neoplasms by Histologic Type (25) · Chronic Disease (24) · Disease Attributes (24) · Leukemia (24) · Leukemia, B-Cell (24) · Pathologic Processes (24) · Pathological Conditions, Signs and Symptoms (24)
Rituximab (4) · Cyclophosphamide (3) · Pharmacogenomic Testing (3) · fludarabine phosphate (3) · Cyclosporine (2) · Lenalidomide (2) · Mycophenolic Acid (2) · acalabrutinib (2) · alvocidib (2) · 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (1) · Antilymphocyte Serum (1) · Azacitidine (1) · Biopsy (1) · Bortezomib (1) · Busulfan (1)
National Cancer Institute (NCI) (10) · Chinese PLA General Hospital (3) · Acerta Pharma BV (2) · Fred Hutchinson Cancer Center (2) · Amir Mortazavi (1) · City of Hope Medical Center (1) · Jennifer Woyach (1) · M.D. Anderson Cancer Center (1) · Ohio State University Comprehensive Cancer Center (1) · Pierluigi Porcu (1) · University of Pennsylvania (1) · Wake Forest University Health Sciences (1)
United States (22) · China (3) · Canada (1) · Germany (1) · Italy (1) · United Kingdom (1)
Jennifer Woyach, MD (2) · Amir Mortazavi, MD (1) · Chitra Hosing (1) · Colleen Delaney (1) · David Maloney (1) · Jeffrey Jones (1) · Jennifer Brown (1) · John Deeken (1) · John Williamson (1) · Joseph Flynn (1) · Kerry Rogers, MD (1) · Kristie Blum (1) · Leslie Andritsos (1)
PMID 34515338, PMID 22259028, PMID 24474568, PMID 25317870, PMID 25444722, PMID 26641137, PMID 26853648, PMID 26943915, PMID 28270022, PMID 28714866, PMID 29263894, PMID 30562587, PMID 31076448, PMID 31088809, PMID 31815579, PMID 31876911, PMID 31915195, PMID 32245502, PMID 32499241, PMID 33492438, PMID 34608724, PMID 34735860, PMID 39563886, PMID 39716442, PMID 41044668, PMID 41804087, PMID 41915892
P30CA016058 (6), U01CA076576 (5), 2014 (1), 2023 (1), N01CM00070 (1), N01CM62207 (1), P30CA015704 (1), P30CA016672 (1), P50CA140158 (1), R21CA115048 (1), R24HL074445 (1), R43HL106868 (1), RC2HL101844 (1), U01CA062487 (1), U01CA062490 (1)